Login to Your Account

Eylea Follow-up Phase III Data Fail to Impress

By Marie Powers
Staff Writer

Tuesday, December 6, 2011
Reaction was mixed on Monday when Regeneron Pharmaceuticals Inc. reported two-year data suggesting that newly approved Eylea (aflibercept) injection in wet age-related macular degeneration (AMD) offered only modest benefit in a head-to-head comparison with market-leading VEGF inhibitor Lucentis (ranibizumab, Genentech Inc./Roche AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription